BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19432119)

  • 1. [Combination therapy for osteoporosis].
    Kishimoto H
    Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of SERMs on bone health. Combination therapy with raloxifene].
    Gorai I; Hori H
    Clin Calcium; 2010 Mar; 20(3):408-12. PubMed ID: 20190371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination therapy for osteoporosis].
    Hagino H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():316-20. PubMed ID: 18161124
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of combination regimens for osteoporosis--prevention and treatment.
    Miller E; Kalin MF
    Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].
    Miki T; Saito S
    Clin Calcium; 2006 Jan; 16(1):167-74. PubMed ID: 16397368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone treatment for osteoporosis.
    Cosman F
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):495-501. PubMed ID: 18971677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonate therapy for osteoporosis and bone strength].
    Kishimoto H
    Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
    Hamano T
    Clin Calcium; 2010 Mar; 20(3):373-9. PubMed ID: 20190367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of osteoporosis with antiresorptive drugs].
    Vestergaard P; Mosekilde L; Brixen K
    Ugeskr Laeger; 2005 Feb; 167(8):883-7. PubMed ID: 15789840
    [No Abstract]   [Full Text] [Related]  

  • 13. [Postmenopausal osteoporosis].
    László A
    Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2002 Nov; 1(3):13-8. PubMed ID: 15529101
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis.
    Garcés C; García LE
    Maturitas; 2006 Apr; 54(1):47-54. PubMed ID: 16257150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis.
    Howard E; Tagliarino-Jones H
    Am Fam Physician; 2010 Feb; 81(4):439. PubMed ID: 20148496
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].
    Tanaka I; Oshima H
    Nihon Rinsho; 2009 May; 67(5):915-20. PubMed ID: 19432109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.